bioAffinity Technologies, Inc. BIAF 深 滬
等待開盤 06-25 09:30:00 美东时间
0.8505
+0.007
+0.87%
華盛通- 最 高0.87
- 今 開0.824
- 成交量 35.62万股
- 最 低 0.82
- 昨 收 0.8432
- 總市值 743.60万
- 52周最高 11.25
- 市盈率 靜 --
- 換手率 4.07%
- 52周最低 0.693
- 委 比 -46.90%
- 總股本 874.31万
- 歷史最高 466.50
- 量 比 0.24
- 振 幅 5.93%
- 歷史最低 0.693
- 每 手 1
- 風險率 2.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多bioAffinity To Present Preclinical Findings For Therapeutic Approach That Uses siRNAs That Kill Squamous And Basal Skin Cancer Cells In Vitro At 2026 RNA Therapeutics Symposium
Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at 2026 RNA Therapeutics Symposium June 24-26 bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnost...
06-22 20:07
bioAffinity Technologies Prices $3.2M Offering Of 4M Shares (Or Pre-funded Warrants) At $0.80/Share ($0.793/Warrant)
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced that it has priced a Public Offering of securities as described below for aggregate ...
06-17 21:26
bioAffinity Receives Mexican Institute Of Industrial Property Allowance For A Patent Application Regarding Methods Of Predicting The Likelihood Of Lung Cancer Using Flow Cytometry
Upon issuance, the Mexican patent application will protect the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer
05-27 20:07
bioAffinity Technologies Reports Record Monthly Unit Sales Of CyPath Lung Diagnostic Tests, 300% Increase In Sales YoY
bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:Expansion of ordering physician sitesIncreased
05-12 21:19
bioAffinity Technologies Q1 EPS $(0.81) Beats $(2.70) Estimate, Sales $1.352M Miss $1.553M Estimate
bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(2.70) by 70 percent. This is a 83.13 percent increase over losses of $(4.80) per share
05-08 20:38
bioAffinity Partners With U.S. Military Medical Center To Develop AI-Driven Diagnostics For Asthma And COPD
Collaboration with nation's largest military medical center focuses on bioAffinity Technologies' pipeline of solutions to address debilitating respiratory diseasesStudy to explore the potential for proprietary flow
04-28 21:16
美股夜盘 | 柏雅国际涨91.93%，Aspire Biopharma Holdings, Inc.涨21.57%
柏雅国际涨91.93%；Aspire Biopharma Holdings, Inc.涨21.57%；联掌门户涨15.87%
04-21 10:01
bioAffinity Technologies shares are trading higher after the company announced a year-over-year increase in its Q1 CyPath Lung Diagnostic unit sales.
bioAffinity Technologies shares are trading higher after the company announced ...
04-01 20:09
美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%，Epsium Enterprise涨20.73%
Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨76.68%；Epsium Enterprise涨20.73%；网络齿轮通信涨14.73%
03-24 09:03
美股夜盘 | Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares涨52.99%，Thryv Holdings, Inc.涨20.88%
Ambitions Enterprise Management涨-16.07%；Powell Max Limited Class A涨-12.06%；bioAffinity Technologies, Inc.涨-11.42%
03-24 08:11
